Geode Capital Management
ACHL

Geode Capital Management’s Achilles Therapeutics ACHL Stock Holding History

Geode Capital Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,590
Closed -$24.6K – 4525
2024
Q4 		$24.6K Hold
21,590
– – ﹤0.01% 4363
2024
Q3 		$22K Hold
21,590
– – ﹤0.01% 4385
2024
Q2 		$17.6K Hold
21,590
– – ﹤0.01% 4474
2024
Q1 		$27K Hold
21,590
– – ﹤0.01% 4436
2023
Q4 		$19.2K Hold
21,590
– – ﹤0.01% 4523
2023
Q3 		$19.6K Hold
21,590
– – ﹤0.01% 4631
2023
Q2 		$20.4K Hold
21,590
– – ﹤0.01% 4653
2023
Q1 		$20.7K Hold
21,590
– – ﹤0.01% 4698
2022
Q4 		$19K Hold
21,590
– – ﹤0.01% 4777
2022
Q3 		$48K Hold
21,590
– – ﹤0.01% 4776
2022
Q2 		$54K Hold
21,590
– – ﹤0.01% 4760
2022
Q1 		$63K Buy
21,590
+3,999
+23% +$14.2K ﹤0.01% 4765
2021
Q4 		$88K Hold
17,591
– – ﹤0.01% 4761
2021
Q3 		$137K Buy
+17,591
New +$116K ﹤0.01% 4577

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Geode Capital Management's ACHL Position: Q1 2025 in Review

Geode Capital Management sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 21,590 shares — an estimated $24.6K sold.

Geode Capital Management first reported a position in ACHL in Q3 2021 and held it in 14 quarters. The position peaked at $137K in Q3 2021. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Geode Capital Management reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Geode Capital Management sold 21,590 Achilles Therapeutics shares in Q1 2025, an estimated $24.6K.
  • Geode Capital Management first reported a position in Achilles Therapeutics in Q3 2021 and held it in 14 quarters.
  • Geode Capital Management's Achilles Therapeutics position peaked at $137K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.